Track topics on Twitter Track topics that are important to you
A phase 2 study of Apellis Pharmaceuticals’ APL-2 for geographic atrophy in age-related macular degeneration has met its primary endpoint at 12 months, according to a company press release.APL-2 injected intravitreally monthly in the multicenter, randomized, single-masked FILLY trial statistically significantly reduced the rate of geographic atrophy lesion growth 29% compared with sham (P = .008). Every-other-month administration reduced the rate 20% (P = .067), the release said.
Original Article: Apellis’ geographic atrophy treatment meets phase 2 endpointNEXT ARTICLE
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...